Take a trial of UK to unlock this pageFind out more
© Stockopedia 29th May, 2017

GlaxoSmithKline

GSK 1643.5p 25.5  1.6%
26/05/17 1.50k


« All RNS

GLAXOSMITHKLINE | Transaction In Own Shares | RNS

RNS Number : 5996X
GlaxoSmithKline PLC
16 February 2012
 



GlaxoSmithKline plc (the "Company") announces that in accordance with the authority granted by shareholders at the Company's Annual General Meeting on 5 May 2011 it purchased 420,000 of its Ordinary shares of 25 pence each ("shares") on 16 February 2012.

 

The highest price paid per share was 1,426.5 pence per share.

The lowest price paid per share was 1,404.0 pence per share.

The Company intends to hold these shares in Treasury.

 

The Company holds 502,862,927 of its shares in Treasury, representing 9.05% of the total issued share capital of the Company. 

 

Including shares which have been purchased but not yet settled, the Company holds 504,192,927 of its shares in Treasury, representing 9.98% of the total voting rights in the Company.

 

The Company has 5,050,618,069 shares in issue (excluding shares held in Treasury). This number represents the total voting rights in the Company and may be used by shareholders as the denominator for the calculations by which they can determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Services Authority's Disclosure and Transparency Rules.

 

This announcement does not constitute, or form part of, an offer or any solicitation of an offer to purchase or subscribe for securities in any jurisdiction and is in conformity with the Financial Services Authority's Disclosure and Transparency Rules.


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
POSLLFVDFTIRLIF



GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases. The Company makes a range of prescription medicines, vaccines and consumer healthcare products. The Pharmaceuticals business discovers, develops and commercializes medicines to treat a range of acute and chronic diseases. The Vaccines business provides vaccines for people of all ages from babies and adolescents to adults and older people. The Consumer Healthcare business develops and markets products in Wellness, Oral health, Nutrition and Skin health categories. Its product portfolio includes Adartrel, Bexsero, Daraprim and Quinvaxem. Its brands include Panadol, abreva, polident and physiogel. more »

LSE Price
1643.5p
Change
1.6%
Mkt Cap (£m)
80,818
P/E (fwd)
14.6
Yield (fwd)
4.9


 
Let’s get you setup so you get the most out of our service
Done, Let's add some stocks
Brilliant - You've created a folio! Now let's add some stocks to it.

  • Apple (AAPL)

  • Shell (RDSA)

  • Twitter (TWTR)

  • Volkswagon AG (VOK)

  • McDonalds (MCD)

  • Vodafone (VOD)

  • Barratt Homes (BDEV)

  • Microsoft (MSFT)

  • Tesco (TSCO)
Save and show me my analysis